Chimeric Therapeutics Limited (CHMMF)
USD 0.0
(0.0%)
USD 0.0
(0.0%)
| Breakdown | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Operating Cash Flow | -7.54 Million | -16.31 Million | -13.15 Million | -8.84 Million | -34 Thousand |
| Net Income | -12.52 Million | -25.91 Million | -15.89 Million | -15.11 Million | -64 Thousand |
| Depreciation & Amortization | 3922.00 | 965.35 Thousand | 949.76 Thousand | 846.96 Thousand | - |
| Deferred income taxes | - | -1.5 Million | -7.37 Million | -1.23 Million | - |
| Stock-based compensation | - | 3.32 Million | 3.16 Million | 2.1 Million | - |
| Change in working capital | - | 3.84 Million | -2.21 Million | 2.33 Million | 30 Thousand |
| Other non-cash items | 4.98 Million | 2.97 Million | 8.21 Million | 2.22 Million | 72 Thousand |
| Investing Cash Flow | - | -112.19 Thousand | -564.87 Thousand | -5.3 Million | - |
| Investments in PPE | - | -112.19 Thousand | -537.85 Thousand | -5.3 Million | - |
| Acquisitions | - | - | - | - | - |
| Investment purchases | - | - | -40 Thousand | - | - |
| Sales/Maturities of investments | - | - | - | - | - |
| Other Investing Activities | - | -112.19 Thousand | 12.97 Thousand | 2646.00 | - |
| Financing Cash Flow | 8.26 Million | 253.37 Thousand | 9.5 Million | 36.54 Million | 34.1 Thousand |
| Debt repayment | - | -2.22 Million | -4.08 Million | -34 Thousand | -34 Thousand |
| Dividends payments | - | - | - | - | - |
| Common Stock Repurchased | - | -88.81 Thousand | -1.3 Million | -2.71 Million | - |
| Common Stock Issuance | 10.54 Million | 2.57 Million | 14.89 Million | 36.58 Million | 100.00 |
| Other Financing Activities | -2.27 Million | -10.3 Thousand | 4.04 Million | 36.54 Million | 81.85 Thousand |
| Accounts receivables | - | -993.36 Thousand | -2.63 Million | -24.24 Thousand | - |
| Accounts payables | - | 4.74 Million | 322.69 Thousand | 2.58 Million | - |
| Inventory | - | - | - | - | - |
| Other working capital | - | 100.84 Thousand | 99.2 Thousand | -230.62 Thousand | 30 Thousand |
| Cash at beginning of period | 5.36 Million | 18.38 Million | 22.41 Million | 100.00 | - |
| Cash at end of period | 3.05 Million | 2.36 Million | 18.38 Million | 22.41 Million | 100.00 |
| Capital Expenditure | - | -112.19 Thousand | -537.85 Thousand | -5.3 Million | - |
| Effect of forex changes on cash | - | 145.69 Thousand | 162.3 Thousand | 8503.00 | - |
| Net cash flow / Change in cash | -2.31 Million | -16.01 Million | -4.02 Million | 22.41 Million | 100.00 |
| Free Cash Flow | -7.54 Million | -16.42 Million | -13.69 Million | -14.14 Million | -34 Thousand |
| Breakdown | 2024 Q4 | 2024 FY | 2024 Q2 | 2024 Q1 | 2023 Q4 | 2023 FY |
|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | - | - | - |
| Net Income | -14.97 Million | -12.52 Million | 2.44 Million | 1.22 Million | -14.16 Million | -25.91 Million |
| Depreciation & Amortization | - | 3922.00 | 486.77 Thousand | 243.38 Thousand | 243.39 Thousand | 965.35 Thousand |
| Deferred income taxes | - | - | - | - | -404.79 Thousand | -1.5 Million |
| Stock-based compensation | - | - | 317.8 Thousand | 317.8 Thousand | 658.08 Thousand | 3.32 Million |
| Change in working capital | - | - | - | - | -446.26 Thousand | 3.84 Million |
| Other non-cash items | 12.08 Million | 4.98 Million | -6.61 Million | -4.12 Million | 10.52 Million | 2.97 Million |
| Investing Cash Flow | - | - | 11.71 Thousand | 11.71 Thousand | -112.19 Thousand | -112.19 Thousand |
| Investments in PPE | - | - | - | - | -112.19 Thousand | -112.19 Thousand |
| Acquisitions | - | - | - | - | - | - |
| Investment purchases | - | - | - | - | - | - |
| Sales/Maturities of investments | - | - | - | - | - | - |
| Other Investing Activities | - | - | 11.71 Thousand | 11.71 Thousand | -63.89 Thousand | -112.19 Thousand |
| Financing Cash Flow | 2.39 Million | 8.26 Million | 5.87 Million | 2.93 Million | 2.48 Million | 253.37 Thousand |
| Debt repayment | - | - | -910 Thousand | - | -2.22 Million | -2.22 Million |
| Dividends payments | - | - | - | - | - | - |
| Common Stock Repurchased | - | - | - | - | - | -88.81 Thousand |
| Common Stock Issuance | 3.76 Million | 10.54 Million | 6.78 Million | - | 2.48 Million | 2.57 Million |
| Other Financing Activities | -2.27 Million | -2.27 Million | 2.93 Million | 2.93 Million | -2.22 Million | -10.3 Thousand |
| Accounts receivables | - | - | - | - | -496.68 Thousand | -993.36 Thousand |
| Accounts payables | - | - | - | - | - | 4.74 Million |
| Inventory | - | - | - | - | - | - |
| Other working capital | - | - | - | - | 50.42 Thousand | 100.84 Thousand |
| Cash at beginning of period | 3.52 Million | 5.36 Million | 5.36 Million | - | 3.62 Million | 18.38 Million |
| Cash at end of period | 3.05 Million | 3.05 Million | 3.52 Million | 581.37 Thousand | 5.36 Million | 2.36 Million |
| Capital Expenditure | - | - | - | - | -112.19 Thousand | -112.19 Thousand |
| Effect of forex changes on cash | - | - | -24.96 Thousand | -24.96 Thousand | 1992.00 | 145.69 Thousand |
| Net cash flow / Change in cash | -472.4 Thousand | -2.31 Million | -1.84 Million | 581.37 Thousand | 1.74 Million | -16.01 Million |
| Free Cash Flow | -2.89 Million | -7.54 Million | -4.65 Million | -2.34 Million | -3.75 Million | -16.42 Million |
AMX
8742
IBE1
DBO
4432
9161